
AU  - Grace, Peter M.
AU  - Watkins, Linda R.
AU  - Hutchinson, Mark R.
C7  - pp. 176-197
TI  - Immune-to-Brain Communication in Pain: Historical Perspectives, New Directions
SN  - 9781119979517
UR  - https://doi.org/10.1002/9781118314814.ch9
DO  - doi:10.1002/9781118314814.ch9
SP  - 176-197
KW  - glial activation
KW  - immune system
KW  - nerve injury
KW  - neuropathic pain
KW  - pathological pain processing
PY  - 2013
AB  - Summary Symptoms of neuropathic pain are often severely debilitating, such as spontaneous pain and dysaesthesia, and the exaggerated pain states of allodynia and hyperalgesia. Research of recent years has shown pain is not modality-specific, but rather that pain processing is an integrated matrix that occurs at the peripheral, spinal, and supraspinal sites. This chapter describes neuronal pain-processing matrix. It summarizes the neuronal adaptations that contribute to pathological pain processing. Such an overview of these neuronal systems is vital to understanding where and how the immune system can modulate pain processing. Whilst glial activation could be demonstrated experimentally, the manner in which glia are activated following nerve injury was still unresolved. Apart from activation by the neurotransmitters and neuromodulators released from the presynaptic terminals of nociceptive primary afferents, much of glial activation can be understood from their immunocompetent status.
ER  - 

TY  - JOUR
TI  - Poster Session Abstracts
JO  - Pediatric Pulmonology
JA  - Pediatr Pulmonol.
VL  - 48
IS  - S36
SN  - 9781119979517
UR  - https://doi.org/10.1002/ppul.22898
DO  - doi:10.1002/ppul.22898
SP  - 207
EP  - 453
PY  - 2013
ER  - 

TY  - JOUR
TI  - Poster abstracts
JO  - Transfusion Alternatives in Transfusion Medicine
VL  - 10
IS  - s1
SN  - 9781119979517
UR  - https://doi.org/10.1111/j.1778-428X.2008.00098.x
DO  - doi:10.1111/j.1778-428X.2008.00098.x
SP  - 20
EP  - 50
PY  - 2008
ER  - 

AU  - Sándor, George K.B.
AU  - Carmichael, Robert P.
AU  - Ylikontiola, Leena P.
AU  - Jan, Ahmed
AU  - DuVal, Marc G.
AU  - Clokie, Cameron M.L.
C7  - pp. 347-395
TI  - Healing of Large Dentofacial Defects
SN  - 9780813804811
UR  - https://doi.org/10.1002/9781118704509.ch15
DO  - doi:10.1002/9781118704509.ch15
SP  - 347-395
KW  - Alveolar distraction osteogenesis (ADO)
KW  - Dentofacial defects and periosteal healing
KW  - Gap osseous healing and bone grafts
KW  - Growth factors and angiogenesis
KW  - Human embryonic stem cells (hESC)
KW  - Hyperbaric oxygen therapy (HBOT)
KW  - Necrotizing fasciitis (NF)
KW  - Osteogenesis and maxillectomy cavities
KW  - Primary bone healing and secondary bone healing
KW  - Vasculoendothelial growth factor (VEGF) effects
PY  - 2008
AB  - Summary This chapter contains sections titled: Introduction The Need for Bone Bone Healing Surgical Maneuvers to Induce and Promote Healing of Large Defects Specifically Difficult Wounds Conclusions References
ER  - 

TY  - JOUR
TI  - Poster Presentations
JO  - Internal Medicine Journal
JA  - Intern Med J
VL  - 49
IS  - S5
SN  - 9780813804811
UR  - https://doi.org/10.1111/imj.14678
DO  - doi:10.1111/imj.14678
SP  - 19
EP  - 34
PY  - 2019
ER  - 

TY  - JOUR
AU  - Braune, Steffen
AU  - Latour, Robert A.
AU  - Reinthaler, Markus
AU  - Landmesser, Ulf
AU  - Lendlein, Andreas
AU  - Jung, Friedrich
C7  - 1900527
TI  - In Vitro Thrombogenicity Testing of Biomaterials
JO  - Advanced Healthcare Materials
JA  - Adv. Healthcare Mater.
VL  - 8
IS  - 21
SN  - 9780813804811
UR  - https://doi.org/10.1002/adhm.201900527
DO  - doi:10.1002/adhm.201900527
SP  - 1900527
KW  - biomaterials
KW  - blood tests
KW  - implants
KW  - in vitro
KW  - thrombogenicity
PY  - 2019
AB  - Abstract The short- and long-term thrombogenicity of implant materials is still unpredictable, which is a significant challenge for the treatment of cardiovascular diseases. A knowledge-based approach for implementing biofunctions in materials requires a detailed understanding of the medical device in the biological system. In particular, the interplay between material and blood components/cells as well as standardized and commonly acknowledged in vitro test methods allowing a reproducible categorization of the material thrombogenicity requires further attention. Here, the status of in vitro thrombogenicity testing methods for biomaterials is reviewed, particularly taking in view the preparation of test materials and references, the selection and characterization of donors and blood samples, the prerequisites for reproducible approaches and applied test systems. Recent joint approaches in finding common standards for a reproducible testing are summarized and perspectives for a more disease oriented in vitro thrombogenicity testing are discussed.
ER  - 

TY  - JOUR
TI  - TUESDAY PLENARY SESSION 3  TUESDAY: POSTERS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1423-0410.2005.00654.x
DO  - doi:10.1111/j.1423-0410.2005.00654.x
SP  - 134
EP  - 199
PY  - 2005
ER  - 

TY  - JOUR
TI  - WEDNESDAY PLENARY SESSION 4  WEDNESDAY PARALLEL SESSIONS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1423-0410.2005.00655.x
DO  - doi:10.1111/j.1423-0410.2005.00655.x
SP  - 200
EP  - 209
PY  - 2005
ER  - 

TY  - JOUR
TI  - Abstracts of the 76th Annual Meeting of the Japanese Cancer Association; 2017 Sept 28-30; Yokohama, Japan
JO  - Cancer Science
JA  - Cancer Sci
VL  - 109
IS  - S1
SN  - 9780813804811
UR  - https://doi.org/10.1111/cas.13499
DO  - doi:10.1111/cas.13499
SP  - 1
EP  - 1325
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts cont.
JO  - Clinical Microbiology and Infection
VL  - 10
IS  - s3
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1469-0691.2004.00903.x
DO  - doi:10.1111/j.1469-0691.2004.00903.x
SP  - 544
EP  - 676
PY  - 2004
ER  - 

TY  - JOUR
TI  - EDUCATION DAY  MONDAY: PLENARY SESSION 1  MONDAY: PARALLEL SESSIONS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1423-0410.2005.00651.x
DO  - doi:10.1111/j.1423-0410.2005.00651.x
SP  - 1
EP  - 27
PY  - 2005
ER  - 

TY  - JOUR
TI  - 45th Annual Meeting of the Arbeitsgemeinschaft Dermatologische Forschung (ADF) Zurich, Switzerland, March 7-10, 2018
JO  - Experimental Dermatology
JA  - Exp Dermatol
VL  - 27
IS  - 3
SN  - 9780813804811
UR  - https://doi.org/10.1111/exd.13486
DO  - doi:10.1111/exd.13486
SP  - e2
EP  - e106
PY  - 2018
ER  - 

TY  - JOUR
TI  - MONDAY: POSTERS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1423-0410.2005.00652.x
DO  - doi:10.1111/j.1423-0410.2005.00652.x
SP  - 28
EP  - 111
PY  - 2005
ER  - 

TY  - JOUR
TI  - TUESDAY: PLENARY SESSION 2  TUESDAY: PARALLEL SESSIONS
JO  - Vox Sanguinis
VL  - 89
IS  - s1
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1423-0410.2005.00653.x
DO  - doi:10.1111/j.1423-0410.2005.00653.x
SP  - 112
EP  - 133
PY  - 2005
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Wound Repair and Regeneration
JA  - Wound Repair Regen
VL  - 20
IS  - 5
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1524-475X.2012.00834.x
DO  - doi:10.1111/j.1524-475X.2012.00834.x
SP  - A83
EP  - A121
PY  - 2012
ER  - 

TY  - JOUR
TI  - AMERICAN TRANSPLANT CONGRESS 2012 ABSTRACTS
JO  - American Journal of Transplantation
VL  - 12
IS  - s3
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1600-6143.2012.04112.x
DO  - doi:10.1111/j.1600-6143.2012.04112.x
SP  - 27
EP  - 542
PY  - 2012
ER  - 

TY  - JOUR
TI  - Abstracts Poster
JO  - American Journal of Transplantation
VL  - 9
IS  - s2
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1600-6143.2009.02659.x
DO  - doi:10.1111/j.1600-6143.2009.02659.x
SP  - 384
EP  - 729
PY  - 2009
ER  - 

TY  - JOUR
TI  - Abstracts - Monday 23rd July 2001
JO  - Scandinavian Journal of Immunology
VL  - 54
IS  - s1
SN  - 9780813804811
UR  - https://doi.org/10.1046/j.1365-3083.2001.0540s1001.x
DO  - doi:10.1046/j.1365-3083.2001.0540s1001.x
SP  - 1
EP  - 1
PY  - 2001
ER  - 

TY  - JOUR
AU  - Shen, Yuh-Chiang
AU  - Wang, Yea-Hwey
AU  - Chou, Yueh-Ching
AU  - Liou, Kuo-Tong
AU  - Yen, Jiin-Cherng
AU  - Wang, Wen-Yen
AU  - Liao, Jyh-Fei
TI  - Dimemorfan protects rats against ischemic stroke through activation of sigma-1 receptor-mediated mechanisms by decreasing glutamate accumulation
JO  - Journal of Neurochemistry
VL  - 104
IS  - 2
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1471-4159.2007.05058.x
DO  - doi:10.1111/j.1471-4159.2007.05058.x
SP  - 558
EP  - 572
KW  - cerebral ischemia-reperfusion
KW  - dimemorfan
KW  - glutamate
KW  - inflammation
KW  - neuroprotection
KW  - oxidative/nitrosative stress
KW  - σ1 receptor
PY  - 2008
AB  - Abstract Dimemorfan, an antitussive and a sigma-1 (σ1) receptor agonist, has been reported to display neuroprotective properties. We set up an animal model of ischemic stroke injury by inducing cerebral ischemia (for 1?h) followed by reperfusion (for 24?h) (CI/R) in rats to examine the protective effects and action mechanisms of dimemorfan against stroke-induced damage. Treatment with dimemorfan (1.0??g/kg and 10??g/kg, i.v.) either 15?min before ischemia or at the time of reperfusion, like the putative σ1 receptor agonist, PRE084 (10??g/kg, i.v.), ameliorated the size of the infarct zone by 67?72% or 51?52%, respectively, which was reversed by pre-treatment with the selective σ1 receptor antagonist, BD1047 (20??g/kg, i.v.). Major pathological mechanisms leading to CI/R injury including excitotoxicity, oxidative/nitrosative stress, inflammation, and apoptosis are all downstream events initiated by excessive accumulation of extracellular glutamate. Dimemorfan treatment (10??g/kg, i.v., at the time of reperfusion) inhibited the expressions of monocyte chemoattractant protein-1 and interleukin-1?, which occurred in parallel with decreases in neutrophil infiltration, activation of inflammation-related signals (p38 mitogen-activated protein kinase, nuclear factor-?B, and signal transducer and activator of transcription-1), expression of neuronal and inducible nitric oxide synthase, oxidative/nitrosative tissue damage (lipid peroxidation, protein nitrosylation, and 8-hydroxy-guanine formation), and apoptosis in the ipsilateral cortex after CI/R injury. Dimemorfan treatment at the time of reperfusion, although did not prevent an early rise of glutamate level, significantly prevented subsequent glutamate accumulation after reperfusion. This inhibitory effect was lasted for more than 4?h and was reversed by pre-treatment with BD1047. These results suggest that dimemorfan activates the σ1 receptor to reduce glutamate accumulation and then suppresses initiation of inflammation-related events and signals as well as induction of oxidative and nitrosative stresses, leading to reductions in tissue damage and cell death. In conclusion, our results demonstrate for the first time that dimemorfan exhibits protective effects against ischemic stroke in CI/R rats probably through modulation of σ1 receptor-dependent signals to prevent subsequent glutamate accumulation and its downstream pathologic events.
ER  - 

TY  - JOUR
TI  - Poster Abstracts
JO  - Vox Sanguinis
VL  - 103
IS  - s1
SN  - 9780813804811
UR  - https://doi.org/10.1111/j.1423-0410.2012.01615_2.x
DO  - doi:10.1111/j.1423-0410.2012.01615_2.x
SP  - 68
EP  - 271
PY  - 2012
ER  - 
